Soham Shukla

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Body Mass Index

Chronic Obstructive Pulmonary Disease

Tyrosine Kinase

Top Venues

International journal of chronic obstructive pulmonary disease

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Robyn Kendall, Alan A Martin, Dhvani Shah, Soham Shukla, Chris Compton, Afisi S Ismaila
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. International journal of chronic obstructive pulmonary disease 18 (2023)
David M G Halpin, Robyn Kendall, Soham Shukla, Alan A Martin, Dhvani Shah, Dawn Midwinter, Kai-Michael Beeh, Janwillem W H Kocks, Paul W Jones, Chris Compton, Nancy A Risebrough, Afisi S Ismaila
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Victoria Neches, Laura Amanda Vallejo-Aparicio, Afisi S Ismaila, Antoni Sicras Mainar, Aram Sicras-Navarro, Cruz González, Rafael Cuervo, Soham Shukla, Marcos García-Peñuela
Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain. International journal of chronic obstructive pulmonary disease 17 (2022)
Soham Shukla, Zachary Babcock, Laura Pizzi, Luigi Brunetti
Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials. Current medical research and opinion 37 (5) (2021)
Soham Shukla, Dhvani Shah, Alan A Martin, Nancy A Risebrough, Robyn Kendall, Claus F Vogelmeier, Isabelle H Boucot, Lee Tombs, Bjermer Leif, Paul W Jones, Edward M Kerwin, Chris Compton, Francois Maltais, David A Lipson, Afisi S Ismaila
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International journal of chronic obstructive pulmonary disease 16 (2021)